JP2016145215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016145215A5 JP2016145215A5 JP2016023519A JP2016023519A JP2016145215A5 JP 2016145215 A5 JP2016145215 A5 JP 2016145215A5 JP 2016023519 A JP2016023519 A JP 2016023519A JP 2016023519 A JP2016023519 A JP 2016023519A JP 2016145215 A5 JP2016145215 A5 JP 2016145215A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- imidazolidinedione
- ethyl
- methyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 27
- 208000016354 hearing loss disease Diseases 0.000 claims 18
- -1 6-{[3- (1-methylethyl) -1,2-benzisoxazol-4-yl] oxy} -3-pyridinyl Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- FTJZGRAFIVZFDZ-UHFFFAOYSA-N 5,5-dimethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O FTJZGRAFIVZFDZ-UHFFFAOYSA-N 0.000 claims 8
- 206010011878 Deafness Diseases 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000004472 Lysine Substances 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000006413 ring segment Chemical group 0.000 claims 8
- LFBFJRDCNKBXII-MRXNPFEDSA-N (5r)-3-[2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1OC(F)(F)O2 LFBFJRDCNKBXII-MRXNPFEDSA-N 0.000 claims 6
- NTIWPSOEUHNVTN-OAQYLSRUSA-N (5r)-3-[2-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1CC(C)(C)OC2 NTIWPSOEUHNVTN-OAQYLSRUSA-N 0.000 claims 6
- MUHADSVSTHSYGD-GFCCVEGCSA-N (5r)-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 MUHADSVSTHSYGD-GFCCVEGCSA-N 0.000 claims 6
- CLAKLXYCHLXXMD-MRXNPFEDSA-N (5r)-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5-propan-2-ylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C(C)C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 CLAKLXYCHLXXMD-MRXNPFEDSA-N 0.000 claims 6
- DEZRPEPAVNAFNI-LLVKDONJSA-N (5r)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1COC2 DEZRPEPAVNAFNI-LLVKDONJSA-N 0.000 claims 6
- BHSLNPYKWBHNJV-GFCCVEGCSA-N (5r)-3-[4-[(3,6-dimethyl-1,2-benzoxazol-4-yl)oxy]phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC(C)=CC2=C1C(C)=NO2 BHSLNPYKWBHNJV-GFCCVEGCSA-N 0.000 claims 6
- CWQPAXHEMUDEFM-CQSZACIVSA-N (5r)-3-[6-[(2,2-dimethyl-3h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1CC(C)(C)O2 CWQPAXHEMUDEFM-CQSZACIVSA-N 0.000 claims 6
- NXFZEVSAUSOECI-JOCHJYFZSA-N (5r)-3-[6-[(3,3-diethyl-1h-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)(CC)OC2 NXFZEVSAUSOECI-JOCHJYFZSA-N 0.000 claims 6
- JXNSTUBOQNDSKJ-JOCHJYFZSA-N (5r)-3-[6-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1CC(C)(C)OC2 JXNSTUBOQNDSKJ-JOCHJYFZSA-N 0.000 claims 6
- BANNWOFBMMRBFI-CYBMUJFWSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 BANNWOFBMMRBFI-CYBMUJFWSA-N 0.000 claims 6
- UFXXLHLRZQDWQK-LLVKDONJSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 UFXXLHLRZQDWQK-LLVKDONJSA-N 0.000 claims 6
- XOWFIAMSTPQWIU-CYBMUJFWSA-N (5r)-5-ethyl-3-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 XOWFIAMSTPQWIU-CYBMUJFWSA-N 0.000 claims 6
- DJHFOZLDQVQSLW-GICMACPYSA-N (5r)-5-ethyl-3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)OC2 DJHFOZLDQVQSLW-GICMACPYSA-N 0.000 claims 6
- DJFNGVMCJLQBNE-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-(2-spiro[2,3-dihydrochromene-4,1'-cyclopropane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C1(CC1)CCO2 DJFNGVMCJLQBNE-HXUWFJFHSA-N 0.000 claims 6
- CPDWLGQBLZMRST-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 CPDWLGQBLZMRST-HXUWFJFHSA-N 0.000 claims 6
- MDESKNKMZVMFSF-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-(7-methylspiro[1h-2-benzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CCC1)OC2 MDESKNKMZVMFSF-OAQYLSRUSA-N 0.000 claims 6
- LMDIRIJUNRBPAD-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(2,4,4-trimethyl-3,1-benzoxazin-5-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)OC(C)=N2 LMDIRIJUNRBPAD-OAQYLSRUSA-N 0.000 claims 6
- DTDJTPCUDZBRJP-JOCHJYFZSA-N (5r)-5-ethyl-5-methyl-3-[6-[(2,4,4-trimethyl-3,1-benzoxazin-5-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)OC(C)=N2 DTDJTPCUDZBRJP-JOCHJYFZSA-N 0.000 claims 6
- WBZCSPNCZZLTMR-LLVKDONJSA-N (5r)-5-methyl-3-[4-[(3-methyl-1,2-benzoxazol-4-yl)oxy]phenyl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1C(C)=NO2 WBZCSPNCZZLTMR-LLVKDONJSA-N 0.000 claims 6
- NPLOCGGQYSBOPP-INIZCTEOSA-N (5r)-5-tert-butyl-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](C(C)(C)C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 NPLOCGGQYSBOPP-INIZCTEOSA-N 0.000 claims 6
- ZICPNWSAKOAKBG-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1CC(C)(C)OC2 ZICPNWSAKOAKBG-UHFFFAOYSA-N 0.000 claims 6
- FGWRIDDFGDQKEH-UHFFFAOYSA-N 5,5-dimethyl-3-(6-spiro[1,3-dihydroisochromene-4,1'-cyclopropane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)COC2 FGWRIDDFGDQKEH-UHFFFAOYSA-N 0.000 claims 6
- BUQRXVHOLHZBJQ-UHFFFAOYSA-N 5,5-dimethyl-3-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 BUQRXVHOLHZBJQ-UHFFFAOYSA-N 0.000 claims 6
- JBUBKHPJMWXPDR-UHFFFAOYSA-N 5,5-dimethyl-3-[4-[(3-methyl-1,2-benzoxazol-4-yl)oxy]phenyl]imidazolidine-2,4-dione Chemical compound C=12C(C)=NOC2=CC=CC=1OC(C=C1)=CC=C1N1C(=O)NC(C)(C)C1=O JBUBKHPJMWXPDR-UHFFFAOYSA-N 0.000 claims 6
- HOUSIKSZRMQPPQ-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[(3-methyl-3,4-dihydro-2h-chromen-5-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C=12CC(C)COC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O HOUSIKSZRMQPPQ-UHFFFAOYSA-N 0.000 claims 6
- ZJEURBVUUVBUMC-UHFFFAOYSA-N 6-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N(C1=O)C(=O)NC21CC2 ZJEURBVUUVBUMC-UHFFFAOYSA-N 0.000 claims 6
- GOPBAXGLRUCBSV-UHFFFAOYSA-N 7-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5,7-diazaspiro[3.4]octane-6,8-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N(C1=O)C(=O)NC21CCC2 GOPBAXGLRUCBSV-UHFFFAOYSA-N 0.000 claims 6
- 231100000888 hearing loss Toxicity 0.000 claims 6
- 230000010370 hearing loss Effects 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- QHYRGKMMPURNST-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)OC2 QHYRGKMMPURNST-OAQYLSRUSA-N 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 208000009205 Tinnitus Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 231100000886 tinnitus Toxicity 0.000 claims 4
- JYJGIGZDJIZOOU-GFCCVEGCSA-N (5r)-3-[4-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 JYJGIGZDJIZOOU-GFCCVEGCSA-N 0.000 claims 3
- JRJFHQWKQUKYGP-PUMZCOHWSA-N (5r)-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1CC1CO2 JRJFHQWKQUKYGP-PUMZCOHWSA-N 0.000 claims 3
- UCUCGUSVXQPQHJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[(3-ethyl-1,2-benzoxazol-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)=NO2 UCUCGUSVXQPQHJ-CYBMUJFWSA-N 0.000 claims 3
- SUGOIOCOVYLITH-SBXXRYSUSA-N (5r)-5-ethyl-3-[6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)OC2 SUGOIOCOVYLITH-SBXXRYSUSA-N 0.000 claims 3
- WGUQZTNFOFTICR-VLFLDKFOSA-N (5r)-5-ethyl-5-methyl-3-[2-[(4-methyl-3,4-dihydro-2h-chromen-5-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)CCO2 WGUQZTNFOFTICR-VLFLDKFOSA-N 0.000 claims 3
- RLZSNZIJMXBLGI-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O RLZSNZIJMXBLGI-UHFFFAOYSA-N 0.000 claims 3
- QKKIXMMFPYSTEH-UHFFFAOYSA-N 3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O QKKIXMMFPYSTEH-UHFFFAOYSA-N 0.000 claims 3
- AOZHFMOQYJFMFL-UHFFFAOYSA-N 3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(CC)OCC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O AOZHFMOQYJFMFL-UHFFFAOYSA-N 0.000 claims 3
- RZIJNHNNRDJJHT-UHFFFAOYSA-N 5,5-dimethyl-3-[2-(7-methylspiro[1h-2-benzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound C1OC2(CCC2)C2=C1C(C)=CC=C2OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O RZIJNHNNRDJJHT-UHFFFAOYSA-N 0.000 claims 3
- FEABXCREHFVJCI-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[(4-methyl-3,4-dihydro-2h-chromen-5-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C=12C(C)CCOC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O FEABXCREHFVJCI-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- MCSCOJJHSDROQX-QGZVFWFLSA-N (5r)-3-[2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1OC(F)(F)O2 MCSCOJJHSDROQX-QGZVFWFLSA-N 0.000 claims 2
- LWGBRPAONSBLOJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 LWGBRPAONSBLOJ-CYBMUJFWSA-N 0.000 claims 2
- VJORKOHZKOIAOJ-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 VJORKOHZKOIAOJ-HXUWFJFHSA-N 0.000 claims 2
- OYFGQTVERWVDGF-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 OYFGQTVERWVDGF-OAQYLSRUSA-N 0.000 claims 2
- CWHUKRBJRARMCX-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 CWHUKRBJRARMCX-OAQYLSRUSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010011903 Deafness traumatic Diseases 0.000 claims 2
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 2
- 206010036626 Presbyacusis Diseases 0.000 claims 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims 2
- 208000002982 auditory neuropathy Diseases 0.000 claims 2
- 231100000895 deafness Toxicity 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- NPNNMBCPDXXEAG-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 NPNNMBCPDXXEAG-CQSZACIVSA-N 0.000 claims 1
- JYHHQTRVJFMEGR-UHFFFAOYSA-N 5,5-dimethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O JYHHQTRVJFMEGR-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/068946 WO2011069951A1 (en) | 2009-12-11 | 2010-12-06 | Imidazolidinedione derivatives |
| GBGB1020607.6A GB201020607D0 (en) | 2010-12-06 | 2010-12-06 | Novel compounds |
| GB1020607.6 | 2010-12-06 | ||
| EPPCT/EP2010/068946 | 2010-12-06 | ||
| GB1109508.0 | 2011-06-07 | ||
| GBGB1109508.0A GB201109508D0 (en) | 2011-06-07 | 2011-06-07 | Novel compounds |
| GBGB1113757.7A GB201113757D0 (en) | 2011-08-10 | 2011-08-10 | Novel compounds |
| GB1113757.7 | 2011-08-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542606A Division JP5913357B2 (ja) | 2010-12-06 | 2011-12-06 | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016145215A JP2016145215A (ja) | 2016-08-12 |
| JP2016145215A5 true JP2016145215A5 (cg-RX-API-DMAC7.html) | 2016-09-23 |
| JP6118927B2 JP6118927B2 (ja) | 2017-04-19 |
Family
ID=45464001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542606A Active JP5913357B2 (ja) | 2010-12-06 | 2011-12-06 | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
| JP2016023519A Active JP6118927B2 (ja) | 2010-12-06 | 2016-02-10 | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542606A Active JP5913357B2 (ja) | 2010-12-06 | 2011-12-06 | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (13) | US9346790B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2649066B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5913357B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101862375B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103328467B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011340258C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013013914B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2817205C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2649066T3 (cg-RX-API-DMAC7.html) |
| EA (2) | EA023768B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2560304T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL226256A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX338489B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2649066T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG190203A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012076877A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201403529B (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2575215T3 (es) * | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| BR112014028991A2 (pt) * | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| PL3092234T3 (pl) | 2013-12-20 | 2018-07-31 | Gilead Sciences, Inc. | Skondensowane związki heterocykliczne jako modulatory kanałów jonowych |
| TR201904712T4 (tr) | 2014-01-16 | 2019-04-22 | Fmc Corp | Herbisitler olarak pirimidiniloksi benzen türevleri. |
| US10183237B2 (en) * | 2014-03-21 | 2019-01-22 | Biotage Ab | Method and apparatus for the equilibration of a packed chromatography column |
| CN103980205B (zh) * | 2014-06-05 | 2016-01-20 | 武汉格罗宁根医药科技有限公司 | N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用 |
| TW202400564A (zh) | 2015-06-05 | 2024-01-01 | 美商艾佛艾姆希公司 | 作為除草劑之嘧啶氧基苯衍生物 |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) * | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| EP3619206B1 (en) * | 2017-05-02 | 2024-02-14 | FMC Corporation | Pyrimidinyloxy benzo-fused compounds as herbicides |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| CN107556262B (zh) * | 2017-08-14 | 2020-05-22 | 四川大学 | 一种2-取代基芳并噁唑的制备方法 |
| US11486289B2 (en) | 2018-07-03 | 2022-11-01 | Cummins Emission Solutions Inc. | Body mixing decomposition reactor |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| AR116713A1 (es) | 2018-10-16 | 2021-06-02 | Autifony Therapeutics Ltd | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 |
| IL311021A (en) | 2018-11-30 | 2024-04-01 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| GB201821066D0 (en) * | 2018-12-21 | 2019-02-06 | Univ Oxford Innovation Ltd | Sleep modulation |
| EP3947365B1 (en) * | 2019-03-25 | 2025-10-01 | Bionomics Limited | Substituted-n-heteroaryl compounds and uses thereof |
| JP7522203B2 (ja) * | 2020-02-06 | 2024-07-24 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３モジュレーター |
| US11638606B2 (en) | 2020-04-15 | 2023-05-02 | Bard Peripheral Vascular, Inc. | Bipolar electrosurgical pleura sealing device, system, and method of operating same |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
| IL310160A (en) | 2021-08-10 | 2024-03-01 | Autifony Therapeutics Ltd | potassium channel modulators |
| WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3474170A (en) * | 1964-01-23 | 1969-10-21 | Fmc Corp | Pesticidal carbamates of dihydrobenzofuranols |
| US4143055A (en) * | 1978-03-27 | 1979-03-06 | Gruppo Lepetit S.P.A. | 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives |
| DE3015090A1 (de) | 1980-04-19 | 1981-10-22 | Basf Ag, 6700 Ludwigshafen | ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen |
| DE3133405A1 (de) | 1981-08-24 | 1983-03-10 | Basf Ag, 6700 Ludwigshafen | 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide |
| US4675403A (en) | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| JP2514945B2 (ja) * | 1987-02-05 | 1996-07-10 | 三井石油化学工業株式会社 | 芳香族アミン誘導体 |
| DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
| DE3836175A1 (de) | 1988-10-24 | 1990-05-03 | Bayer Ag | Fluor enthaltende phenole |
| CA2007830A1 (en) * | 1989-01-18 | 1990-07-18 | Shuji Ozawa | 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them |
| MX22406A (es) | 1989-09-15 | 1994-01-31 | Pfizer | Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat). |
| JPH03153606A (ja) * | 1989-11-10 | 1991-07-01 | Mitsui Petrochem Ind Ltd | 除草剤組成物 |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| DK123493D0 (da) | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
| WO1996036229A1 (en) | 1995-05-17 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| BR9608520A (pt) | 1995-05-17 | 1999-06-08 | Du Pont | Composto composição fungida e método para controlede doenças de plantas |
| CZ394097A3 (cs) | 1995-06-20 | 1998-09-16 | E. I. Du Pont De Nemours And Company | Artropodicidní a fungicidní amidy |
| BR9711816A (pt) | 1996-08-01 | 1999-08-31 | Du Pont | Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes. |
| EP0944314A1 (en) | 1996-11-26 | 1999-09-29 | E.I. Du Pont De Nemours And Company | Methyl substituted fungicides and arthropodicides |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| AU6040398A (en) | 1997-01-30 | 1998-08-25 | E.I. Du Pont De Nemours And Company | Fungicidal compositions |
| JP4171549B2 (ja) | 1998-01-28 | 2008-10-22 | 大正製薬株式会社 | 含フッ素アミノ酸誘導体 |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| JP2000072731A (ja) | 1998-08-31 | 2000-03-07 | Taisho Pharmaceut Co Ltd | ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物 |
| HK1046645A1 (zh) | 1999-07-23 | 2003-01-24 | 盐野义制药株式会社 | Th2分化抑制剂 |
| US20030149061A1 (en) | 2000-04-04 | 2003-08-07 | Yoshitaka Nishihara | Oily compositions containing highly fat-soluble drugs |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| WO2003048134A1 (en) | 2001-12-05 | 2003-06-12 | Japan Tobacco Inc. | Triazole compound and medicinal use thereof |
| MXPA04007719A (es) | 2002-02-07 | 2005-09-08 | Univ Missouri | Compuestos 4-(3hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos del receptor opioide. |
| FI20030030A0 (fi) * | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CA2524221A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| GB0325175D0 (en) | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| US20060211697A1 (en) | 2004-12-08 | 2006-09-21 | Liren Huang | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| KR102481886B1 (ko) | 2005-05-13 | 2022-12-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| CN102755318B (zh) | 2006-03-29 | 2014-09-10 | 加利福尼亚大学董事会 | 二芳基硫代乙内酰脲化合物 |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| CA2678639A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2252592A1 (de) | 2008-02-07 | 2010-11-24 | Sanofi-Aventis | Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| MX2011001821A (es) * | 2008-09-02 | 2011-03-25 | Sanofi Aventis | Aminoindanos sustituidos y sus analogos, y el uso farmaceutico de los mismos. |
| MX2011006647A (es) | 2008-12-22 | 2011-07-12 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| ES2575215T3 (es) * | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| KR20120104343A (ko) | 2009-12-14 | 2012-09-20 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| WO2012076877A1 (en) * | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| CN108472250A (zh) | 2015-10-30 | 2018-08-31 | 约翰霍普金斯大学 | 高分子量粘液穿透颗粒和致密涂层 |
-
2011
- 2011-12-06 WO PCT/GB2011/052414 patent/WO2012076877A1/en not_active Ceased
- 2011-12-06 AU AU2011340258A patent/AU2011340258C1/en active Active
- 2011-12-06 EP EP11805571.4A patent/EP2649066B1/en active Active
- 2011-12-06 MX MX2013006343A patent/MX338489B/es active IP Right Grant
- 2011-12-06 KR KR1020137017537A patent/KR101862375B1/ko active Active
- 2011-12-06 BR BR112013013914-5A patent/BR112013013914B1/pt active IP Right Grant
- 2011-12-06 ES ES11805571.4T patent/ES2560304T3/es active Active
- 2011-12-06 CN CN201180058712.3A patent/CN103328467B/zh active Active
- 2011-12-06 PL PL11805571T patent/PL2649066T3/pl unknown
- 2011-12-06 SG SG2013035357A patent/SG190203A1/en unknown
- 2011-12-06 EA EA201390609A patent/EA023768B1/ru not_active IP Right Cessation
- 2011-12-06 US US13/991,486 patent/US9346790B2/en active Active
- 2011-12-06 CA CA2817205A patent/CA2817205C/en active Active
- 2011-12-06 DK DK11805571.4T patent/DK2649066T3/en active
- 2011-12-06 JP JP2013542606A patent/JP5913357B2/ja active Active
-
2012
- 2012-12-06 EA EA201490922A patent/EA027532B1/ru not_active IP Right Cessation
- 2012-12-06 US US14/361,510 patent/US9133175B2/en active Active
- 2012-12-06 SG SG11201402529RA patent/SG11201402529RA/en unknown
-
2013
- 2013-05-09 IL IL226256A patent/IL226256A0/en unknown
-
2014
- 2014-05-15 ZA ZA2014/03529A patent/ZA201403529B/en unknown
-
2015
- 2015-08-03 US US14/816,476 patent/US9422272B2/en active Active
-
2016
- 2016-02-10 JP JP2016023519A patent/JP6118927B2/ja active Active
- 2016-04-07 US US15/093,004 patent/US20160251340A1/en not_active Abandoned
- 2016-07-11 US US15/206,465 patent/US9833452B2/en active Active
-
2017
- 2017-06-13 US US15/621,400 patent/US10265316B2/en active Active
- 2017-06-22 IL IL253104A patent/IL253104A0/en unknown
- 2017-06-22 IL IL253102A patent/IL253102B/en active IP Right Grant
- 2017-10-11 US US15/730,559 patent/US10098881B2/en active Active
-
2018
- 2018-09-07 US US16/125,148 patent/US10555945B2/en active Active
-
2019
- 2019-02-26 US US16/285,996 patent/US20190192516A1/en not_active Abandoned
- 2019-12-23 US US16/725,709 patent/US10835534B2/en active Active
-
2020
- 2020-08-04 US US16/985,160 patent/US11197859B2/en active Active
- 2020-09-23 US US17/030,268 patent/US11541052B2/en active Active
-
2021
- 2021-11-02 US US17/517,620 patent/US11583527B2/en active Active